RemeGen

RemeGen has successfully commercialized two world-class drugs—telitacicept for SLE and disitamab vedotin for gastric/urothelial cancers—in China. Telitacicept was the first-in-class dual-target fusion protein approved for SLE in March 2021. Disitamab vedotin became the first Chinese-developed ADC to receive breakthrough therapy designation from both the US FDA and China's NMPA, with approvals for gastric and urothelial cancers. The company has dozens of innovative drugs at various stages of development across oncology, autoimmune, and ophthalmic diseases. It also achieved a record-setting global licensing deal with Seagen for disitamab vedotin.